And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is particularly modest. We hope to catch up on our fast-growing reading list, take a few naps, and hang with a short person or two. We may also putter around the castle. And what about you? Spring is edging closer, so perhaps this is a good time to plan a getaway or get a head start on cleaning out the closets. You could also enjoy a moving picture or make time for someone special. Life is short, you know. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Sanofi (SNY) suffered a major setback in its bid to market its controversial dengue vaccine in the U.S., as a Food and Drug Administration advisory committee recommended against approval for adults, STAT writes. The drug maker had asked the agency to approve Dengvaxia for people aged 9 to 45. But the advisory panel recommended the agency license the vaccine only for people ages 9 to less than 17. Dengvaxia is the first dengue vaccine to make it to market anywhere in the world, but has accompanied by enormous problems and scandal.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy